Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study.

IF 1.8 4区医学 Q2 ACOUSTICS

Medical Ultrasonography Pub Date : 2022-12-21 Epub Date: 2022-06-03 DOI:10.11152/mu-3503

Alina Liliana Constantin, Irina Cazacu, Daniela Elena Burtea, Irina Cherciu Harbiyeli, Nona Bejinariu, Carmen Popescu, Mircea Serbanescu, Daniela Tabacelia, Catalin Copaescu, Manoop Bhutani, Cezar Stroescu, Adrian Saftoiu

{"title":"Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study.","authors":"Alina Liliana Constantin, Irina Cazacu, Daniela Elena Burtea, Irina Cherciu Harbiyeli, Nona Bejinariu, Carmen Popescu, Mircea Serbanescu, Daniela Tabacelia, Catalin Copaescu, Manoop Bhutani, Cezar Stroescu, Adrian Saftoiu","doi":"10.11152/mu-3503","DOIUrl":null,"url":null,"abstract":"Aim: Contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) parameters may be used to predict prognosis of pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumors (pNET). The aim of this study was to investigate the association between several perfusion parameters on CEH-EUS performed before treatment and survival outcome in patients with PDAC or pNET.Material and methods: Thirty patients with PDAC or pNET who underwent CEH-EUS and EUS-guided fine needle aspiration (EUS-FNA) were included. Quantitative analysis of tumor vascularity was performed using time-intensity curve (TIC) analysis-derived parameters, obtained from processing CEH-EUS recordings with a commercially available software (VueBox). Cox proportional hazards models were used to determine associations with survival outcome.Results: Median overall survival (OS) for PDAC patients was 9.61 months (95% CI: 0.1-38.7) while the median OS for pNET patients was 15.81 months (95% CI: 5.8-24.75. In a multivariate model for OS, a lower peak enhancement (HR=1.76, p=0.02) and a lower wash-in area under the curve (HR=1.06, p=0.001) were associated with worse survival outcome for patients with PDAC.Conclusions: CEH-EUS parameters may be used as a surrogate to predict PDAC aggressiveness and survival before treatment. After validation by large-scale studies, CEH-EUS perfusion parameters have the potential to be used in pretreatment risk stratification of patients with PDAC and in evidence-based clinical decision support.","PeriodicalId":48781,"journal":{"name":"Medical Ultrasonography","volume":"24 4","pages":"393-398"},"PeriodicalIF":1.8000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Ultrasonography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11152/mu-3503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ACOUSTICS","Score":null,"Total":0}

引用次数: 2

Abstract

Aim: Contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) parameters may be used to predict prognosis of pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumors (pNET). The aim of this study was to investigate the association between several perfusion parameters on CEH-EUS performed before treatment and survival outcome in patients with PDAC or pNET.

Material and methods: Thirty patients with PDAC or pNET who underwent CEH-EUS and EUS-guided fine needle aspiration (EUS-FNA) were included. Quantitative analysis of tumor vascularity was performed using time-intensity curve (TIC) analysis-derived parameters, obtained from processing CEH-EUS recordings with a commercially available software (VueBox). Cox proportional hazards models were used to determine associations with survival outcome.

Results: Median overall survival (OS) for PDAC patients was 9.61 months (95% CI: 0.1-38.7) while the median OS for pNET patients was 15.81 months (95% CI: 5.8-24.75. In a multivariate model for OS, a lower peak enhancement (HR=1.76, p=0.02) and a lower wash-in area under the curve (HR=1.06, p=0.001) were associated with worse survival outcome for patients with PDAC.

Conclusions: CEH-EUS parameters may be used as a surrogate to predict PDAC aggressiveness and survival before treatment. After validation by large-scale studies, CEH-EUS perfusion parameters have the potential to be used in pretreatment risk stratification of patients with PDAC and in evidence-based clinical decision support.

查看原文本刊更多论文

胰腺导管腺癌和胰腺神经内分泌肿瘤的定量对比增强内镜超声：我们能用灌注参数预测生存率吗？一项试点研究。

目的：对比增强谐波内镜超声（CEH-EUS）参数可用于预测胰腺导管腺癌（PDAC）和胰腺神经内分泌肿瘤（pNET）的预后。本研究旨在探讨在治疗前进行的CEH-EUS检查的几个灌注参数与PDAC或pNET患者生存结果之间的关系：纳入了 30 例接受 CEH-EUS 和 EUS 引导下细针穿刺（EUS-FNA）的 PDAC 或 pNET 患者。利用市售软件（VueBox）处理CEH-EUS记录获得的时间强度曲线（TIC）分析参数对肿瘤血管进行定量分析。采用Cox比例危险模型确定与生存结果的关系：PDAC患者的中位总生存期（OS）为9.61个月（95% CI：0.1-38.7），而pNET患者的中位OS为15.81个月（95% CI：5.8-24.75）。在OS的多变量模型中，较低的峰值增强（HR=1.76，P=0.02）和较低的曲线下冲洗面积（HR=1.06，P=0.001）与PDAC患者较差的生存结果相关：结论：CEH-EUS参数可作为治疗前预测PDAC侵袭性和生存率的替代指标。经过大规模研究验证后，CEH-EUS灌注参数有望用于PDAC患者治疗前风险分层和循证临床决策支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Ultrasonography RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

3.20

自引率

5.90%

发文量

期刊介绍： The journal aims to promote ultrasound diagnosis by publishing papers in a variety of categories, including editorial letters, original papers, review articles, pictorial essays, technical developments, case reports, letters to the editor or occasional special reports (fundamental, clinical as well as methodological and educational papers). The papers published cover the whole spectrum of the applications of diagnostic medical ultrasonography, including basic science and therapeutic applications. The journal hosts information regarding the society''s activities, scheduling of accredited training courses in ultrasound diagnosis, as well as the agenda of national and international scientific events.